Literature DB >> 18835293

Potential of the rat model of conditioned gaping to detect nausea produced by rolipram, a phosphodiesterase-4 (PDE4) inhibitor.

Erin M Rock1, Jessica Benzaquen, Cheryl L Limebeer, Linda A Parker.   

Abstract

Rolipram, a phosphodiesterase-4 (PDE4) inhibitor, is of current interest as a cognitive enhancer and as a treatment for inflammatory diseases. Originally developed as an anti-depressant, rolipram's efficacy was limited due to its side effects of nausea and vomiting. The experiments reported here evaluated the potential of rolipram to produce conditioned gaping (a selective measure of nausea in rats) to a flavor in the taste reactivity test (Experiment 1) and to a context (Experiment 2). In Experiment 1, rats were intra-orally infused with 17% sucrose solution prior to being injected with rolipram (Vehicle, 0.03, 0.1 or 0.3 mg/kg). Following 3 conditioning trials, rats conditioned with 0.3 mg/kg rolipram displayed conditioned gaping reactions during the infusion of sucrose. In Experiment 2, rats received 4 conditioning trials in which they were injected with 0.3 mg/kg rolipram and placed into a distinctive chamber. At test, when returned to the chamber rats displayed conditioned gaping. These results demonstrate the ability of the conditioned gaping model to detect the nauseating properties of a rolipram-paired flavor (Experiment 1) and rolipram-paired context (Experiment 2), further validating the potential use of the conditioned gaping model as a pre-clinical screening tool to evaluate the side effect of nausea produced by newly developed drugs.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18835293     DOI: 10.1016/j.pbb.2008.09.005

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  13 in total

1.  A novel peripherally restricted cannabinoid receptor antagonist, AM6545, reduces food intake and body weight, but does not cause malaise, in rodents.

Authors:  N L Cluny; V K Vemuri; A P Chambers; C L Limebeer; H Bedard; J T Wood; B Lutz; A Zimmer; L A Parker; A Makriyannis; K A Sharkey
Journal:  Br J Pharmacol       Date:  2010-10       Impact factor: 8.739

2.  GEBR-7b, a novel PDE4D selective inhibitor that improves memory in rodents at non-emetic doses.

Authors:  O Bruno; E Fedele; J Prickaerts; L A Parker; E Canepa; C Brullo; A Cavallero; E Gardella; A Balbi; C Domenicotti; E Bollen; H J M Gijselaers; T Vanmierlo; K Erb; C L Limebeer; F Argellati; U M Marinari; M A Pronzato; R Ricciarelli
Journal:  Br J Pharmacol       Date:  2011-12       Impact factor: 8.739

3.  Increased liking for a solution is not necessary for the attenuation of neophobia in rats.

Authors:  Karly N Neath; Cheryl L Limebeer; Steve Reilly; Linda A Parker
Journal:  Behav Neurosci       Date:  2010-06       Impact factor: 1.912

4.  Inverse agonism of cannabinoid CB1 receptors potentiates LiCl-induced nausea in the conditioned gaping model in rats.

Authors:  C L Limebeer; V K Vemuri; H Bedard; S T Lang; K P Ossenkopp; A Makriyannis; L A Parker
Journal:  Br J Pharmacol       Date:  2010-09       Impact factor: 8.739

5.  Evaluation of the potential of the phytocannabinoids, cannabidivarin (CBDV) and Δ(9) -tetrahydrocannabivarin (THCV), to produce CB1 receptor inverse agonism symptoms of nausea in rats.

Authors:  Erin M Rock; Martin A Sticht; Marnie Duncan; Colin Stott; Linda A Parker
Journal:  Br J Pharmacol       Date:  2013-10       Impact factor: 8.739

Review 6.  Phosphodiesterase regulation of alcohol drinking in rodents.

Authors:  Marian L Logrip
Journal:  Alcohol       Date:  2015-05-29       Impact factor: 2.405

7.  The phosphodiesterase-4 (PDE4) inhibitor rolipram decreases ethanol seeking and consumption in alcohol-preferring Fawn-Hooded rats.

Authors:  Rui-Ting Wen; Min Zhang; Wang-Jun Qin; Qing Liu; Wei-Ping Wang; Andrew J Lawrence; Han-Ting Zhang; Jian-Hui Liang
Journal:  Alcohol Clin Exp Res       Date:  2012-06-04       Impact factor: 3.455

Review 8.  Dual PDE3/4 inhibitors as therapeutic agents for chronic obstructive pulmonary disease.

Authors:  Katharine H Banner; Neil J Press
Journal:  Br J Pharmacol       Date:  2009-06-05       Impact factor: 8.739

9.  Orally Available Soluble Epoxide Hydrolase/Phosphodiesterase 4 Dual Inhibitor Treats Inflammatory Pain.

Authors:  René Blöcher; Karen M Wagner; Raghavender R Gopireddy; Todd R Harris; Hao Wu; Bogdan Barnych; Sung Hee Hwang; Yang K Xiang; Ewgenij Proschak; Christophe Morisseau; Bruce D Hammock
Journal:  J Med Chem       Date:  2018-04-10       Impact factor: 7.446

10.  Evaluation of chemically diverse 5-HT₂c receptor agonists on behaviours motivated by food and nicotine and on side effect profiles.

Authors:  G A Higgins; L B Silenieks; W Lau; I A M de Lannoy; D K H Lee; J Izhakova; K Coen; A D Le; P J Fletcher
Journal:  Psychopharmacology (Berl)       Date:  2012-11-25       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.